157 related articles for article (PubMed ID: 17401629)
1. Primary conjunctival follicular lymphoma treated with the anti-CD20 antibody rituximab and low-dose involved-field radiotherapy.
Takahira M; Okumura H; Minato H; Urushisaki N; Sakurai M; Sugiyama K
Jpn J Ophthalmol; 2007; 51(2):149-51. PubMed ID: 17401629
[No Abstract] [Full Text] [Related]
2. Anti-CD20 antibody therapy is highly effective in the treatment of follicular lymphoma.
Marshall H
Trends Immunol; 2001 Apr; 22(4):183-4. PubMed ID: 11274916
[No Abstract] [Full Text] [Related]
3. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
[TBL] [Abstract][Full Text] [Related]
4. Bilateral conjunctival follicular lymphoma in a child.
Wall PB; Traboulsi EI; Hsi ED; Singh AD
J AAPOS; 2015 Apr; 19(2):183-5. PubMed ID: 25824110
[TBL] [Abstract][Full Text] [Related]
5. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
6. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab.
Schmitz K; Brugger W; Weiss B; Kaiserling E; Kanz L
Br J Haematol; 1999 Aug; 106(2):571-2. PubMed ID: 10460626
[No Abstract] [Full Text] [Related]
7. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
[TBL] [Abstract][Full Text] [Related]
8. [90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab].
Aurer I; Huić D; Zuvić M; Sever-Prebilić M; Ajduković R; Radman I; Skare-Librenjak L; Ostojić-Kolonić S; Labar B
Lijec Vjesn; 2006; 128(7-8):224-7. PubMed ID: 17087138
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
[TBL] [Abstract][Full Text] [Related]
10. Primary follicular lymphoma of the small intestine.
Chim CS; Loong F; Leung AY; Tsang J; Ooi GC
Leuk Lymphoma; 2004 Jul; 45(7):1463-6. PubMed ID: 15359649
[TBL] [Abstract][Full Text] [Related]
11. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.
Sokol JA; Landau L; Lauer SA
Ophthalmic Plast Reconstr Surg; 2009; 25(4):322-4. PubMed ID: 19617799
[TBL] [Abstract][Full Text] [Related]
12. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial.
Witzens-Harig M; Hensel M; Unterhalt M; Herfarth K
BMC Cancer; 2011 Feb; 11():87. PubMed ID: 21352561
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
Kennedy GA; Blum R; McCormack C; Prince HM
Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
[TBL] [Abstract][Full Text] [Related]
14. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus.
Borradori L; Lombardi T; Samson J; Girardet C; Saurat JH; Hügli A
Arch Dermatol; 2001 Mar; 137(3):269-72. PubMed ID: 11255323
[No Abstract] [Full Text] [Related]
16. Severe infusion reaction, anti-rituximab antibodies and lymphoma.
Kidoguchi K; Kubota Y; Kusaba K; Kizuka-Sano H; Yamaguchi K; Nishioka A; Yokoo M; Ando T; Kojima K; Kimura S
QJM; 2020 Apr; 113(4):273-274. PubMed ID: 31702763
[No Abstract] [Full Text] [Related]
17. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
Foran JM; Gupta RK; Cunningham D; Popescu RA; Goldstone AH; Sweetenham JW; Pettengell R; Johnson PW; Bessell E; Hancock B; Summers K; Hughes J; Rohatiner AZ; Lister TA
Br J Haematol; 2000 Apr; 109(1):81-8. PubMed ID: 10848785
[TBL] [Abstract][Full Text] [Related]
18. Conjunctival and orbital lymphoma.
Shinder R
Ophthalmology; 2011 Aug; 118(8):1692; author reply 1692, 1692.e1. PubMed ID: 21813098
[No Abstract] [Full Text] [Related]
19. Can Low Dose Radiation Therapy (2 × 2 Gy) be Used in Primary Bilateral Conjunctival Follicular Lymphoma?
Cotting-Bodmer S; Moulin A; Herbort CP; Ketterer N; Betz M; Pica A; Schalenbourg A
Klin Monbl Augenheilkd; 2016 Apr; 233(4):524-6. PubMed ID: 27116528
[No Abstract] [Full Text] [Related]
20. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG.
Saikia TK; Menon H; Advani SH
Ann Oncol; 2001 Oct; 12(10):1493-4. PubMed ID: 11762825
[No Abstract] [Full Text] [Related]
[Next] [New Search]